/News/Research — The new study compared the bioavailability of Lipo CoQ-10 from Specnova using its LipoVantage technology against placebo and standard CoQ10. Participants received a single dose of placebo, or 100 mg of standard CoQ10 or Lipo CoQ-10. “These results suggest that although liposomal CoQ-10 increases bioavailability, a single administration may not be sufficient to induce acute changes in systemic oxidative stress or inflammation,” they wrote. A premium positioningSpecnova’s CEO Sebastian Balcombe told NutraIngredients that the higher bioavailability can lead to lower doses but that there is an extra cost to put it into liposomal form. “It depends how much lower the customer wants to dose down our Liposomal CoQ10,” he said.